What Apex Labs does

Apex Labs Ltd. is a privately held, clinical-stage pharmaceutical company headquartered in Vancouver, British Columbia, developing two patent-pending psilocybin-based drug assets for mental health indications: APEX-52, a microdose formulation intended for take-home use in moderate depression and PTSD, and APEX-90, a macrodose formulation administered in-clinic with assisted psychotherapy for severe cases. The company is currently advancing Phase 2b trials in Canada and Israel, with parallel regulatory engagement in the United States, European Union, and Australia, and has filed an IND with the FDA for its microdose candidate. Both drug candidates have reportedly achieved all endpoints without adverse events in Veteran patient populations across clinical and early access settings.

The company is Veteran-founded and positions Veterans as its primary initial patient segment, leveraging a network of Veteran-focused clinics and advocacy relationships (Wounded Warriors Canada, Heroic Hearts Project, Chronic Pain Centre of Excellence) to drive trial recruitment and, ultimately, market access. Revenue mechanics are pre-commercial: the company has no approved products or disclosed pricing, with intended future streams being pharmaceutical product sales and licensing royalties of proprietary formulations and delivery systems. Distribution is currently limited to clinical trial sites, Health Canada's Special Access Program, and a company-operated Early Access Program. Leadership combines big-pharma commercialization experience (CCO Greg Rutherford, formerly J&J, Roche, GSK, Lilly, McKesson) with clinical CNS expertise (CMO Dr. Mark Johnston).

Name

Apex Labs

Legal name

Apex Labs Ltd.

Website

https://apexlabs.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Apex Labs Ltd. is a Vancouver-based, Veteran-founded clinical-stage pharmaceutical company developing two patent-pending psilocybin-based drug assets — APEX-52 (take-home microdose) and APEX-90 (in-clinic macrodose) — for PTSD and depression, primarily targeting Veteran populations through Phase 2b trials in Canada and Israel.

Ownership category

akta.pro rank

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Once regulatory approval is obtained, Apex Labs plans to commercialize its psilocybin-based drug products (APEX-52 and APEX-90) for treatment of PTSD and depression. The company is in clinical development stage with no current commercial revenue.
2. Licensing Royalties: Potential licensing of proprietary drug formulations and delivery systems to pharmaceutical partners upon regulatory approval in various jurisdictions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Apex Labs is a clinical-stage pharmaceutical company developing two patent-pending psilocybin-based drug assets for the treatment of PTSD and depression. APEX-52 is a microdose formulation designed for take-home use targeting moderate cases, while APEX-90 is a macrodose formulation intended for in-clinic dosing with assisted psychotherapy targeting severe cases. Both candidates are being advanced through Phase 2b clinical trials in Canada and Israel, with regulatory engagement in the US, EU, and Australia.

Product overview

Apex Labs is a patient-driven pharmaceutical company developing two distinct, patent-pending psilocybin-based drug assets for mental health treatment: APEX-52 (Microdose) and APEX-90 (Macrodose). APEX-52 is a take-home microdose formulation targeting moderate depression and PTSD, while APEX-90 is an in-clinic macrodose therapy with assisted psychotherapy for severe cases. Both drug candidates have achieved all clinical endpoints without adverse events in Veteran patient populations. The company is advancing Phase 2b trials in Canada and Israel, with regulatory engagement in the US, EU, and Australia toward global market access.

Differentiator

Problem solved

Functional benefit

Brands

• APEX-52: Microdose formulation designed for take-home use targeting moderate depression and PTSD.
• APEX-90

Products and services

• APEX-52 (Microdose) A patent-pending psilocybin microdose formulation designed for take-home use, targeting moderate depression and PTSD. Optimized for patients who can self-administer outside of clinical settings. Being advanced through clinical development with regulatory engagement in Canada, US, Israel, EU, and Australia.
• APEX-90 (Macrodose) A patent-pending psilocybin macrodose formulation intended for in-clinic dosing with assisted psychotherapy, targeting severe cases of depression and PTSD. Administered under medical supervision. Currently being dosed in Phase 2b clinical trials in Canada and Israel and through the company's Early Access Program for qualified patients.

Quantifiable outcome

• Both drug candidates achieved all endpoints without adverse events in clinical and early access settings
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor.

• Wounded Warriors CanadaminorOthersArron Victory, Chief Strategy Officer and co-Founder, serves as an Ambassador for this Veteran advocacy group that provides support to Veterans and their families.
• Heroic Hearts ProjectminorOthersArron Victory serves as Board Member of this charity that provides access to psychedelic therapies for Veterans.
• Chronic Pain Centre of ExcellenceminorOthersArron Victory serves as Advisory Board Member of this research centre improving understanding of Veteran-specific chronic pain and management strategies.
• Cooley LLPminorImplementation/ SI/ Consulting PartnerIP/patent counsel engaged by Apex Labs for intellectual property development and patent protection strategy in the psychedelics space.
• BLG (Borden Ladner Gervais)minorImplementation/ SI/ Consulting PartnerIP/patent counsel engaged by Apex Labs for intellectual property development and patent protection strategy.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Compass Pathways: Compass Pathways is developing psilocybin therapy (COMP360) for treatment-resistant depression and is the most advanced publicly listed pure-play psilocybin developer. Direct competitor to Apex Labs in psychedelic-based mental health therapeutics with a similar mechanism and clinical development approach.
• MindMed: MindMed is a clinical-stage psychedelic medicine biotech developing LSD and psilocybin-based therapies for anxiety, depression, and ADHD. Direct competitor to Apex Labs in the psychedelic pharmaceutical space, with publicly listed status and broader capital access.
• Small Pharma: Small Pharma is developing SPL026 (DMT) and other psychedelic-based therapies for depression, with clinical programs in the UK. Direct peer focused on psychedelic pharmaceutical drug development, similar size and stage to Apex Labs.
• Cybin Inc. Cybin is developing psilocybin and deuterated psilocybin analogs (CYB003) for depression and other mental health indications. Direct peer in psychedelic drug development with similar indications and a broader deuterated-psilocybin patent strategy.
• Field Trip Health (Delic Corp): Formerly Field Trip Health, Delic operates psychedelic therapy clinics and develops related pharmaceutical assets. Comparable to Apex Labs in the psychedelic mental health space, though more focused on clinic delivery and ketamine-based services.
• GH Research: GH Research is developing psilocybin (GH001) for treatment-resistant depression, with active Phase 2b/3 trials in Europe and the US. Closely comparable to Apex Labs' APEX-90 program in mechanism, indication, and clinical development stage.

Emerging players

• Mydecine Innovations Group: Mydecine is a psychedelic medicine company developing psilocybin and other natural-sourced compounds for mental health indications. Early-stage peer with similar psychedelic drug development focus but smaller and earlier-stage clinical programs.
• Clearmind Medicine: Clearmind is a psychedelic pharmaceutical company developing novel compounds (including non-hallucinogenic options) for addiction and mental health disorders. Emerging peer with partial overlap in psychedelic-based mental health treatment development.

Broad incumbents

• ATAI Life Sciences: ATAI is a clinical-stage biopharmaceutical company developing a portfolio of psychedelic and non-psychedelic mental health therapies, including a controlling stake in Compass Pathways. Broader platform incumbent in psychedelic therapeutics with materially greater capital and pipeline depth.

Regional players

• Numinus Wellness: Numinus is a Canadian-based mental health company operating psychedelic-assisted therapy clinics and a research division. Regional peer in the same Canadian market as Apex Labs, with overlapping interest in psilocybin clinical research and clinic-based service delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ApexLabsLtd
• Facebookfacebook.com/ApexLabsLtd
• LinkedInlinkedin.com/company/apex-labs-ltd
• Instagraminstagram.com/apexlabsltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apex Labs